Atlantic Family Wealth LLC Acquires New Shares in Sanofi (NASDAQ:SNY)

Atlantic Family Wealth LLC bought a new position in Sanofi (NASDAQ:SNY - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 5,431 shares of the company's stock, valued at approximately $262,000.

A number of other hedge funds also recently made changes to their positions in SNY. Abel Hall LLC raised its position in shares of Sanofi by 1.8% during the 4th quarter. Abel Hall LLC now owns 10,990 shares of the company's stock valued at $530,000 after buying an additional 194 shares in the last quarter. PDS Planning Inc raised its position in Sanofi by 3.1% during the third quarter. PDS Planning Inc now owns 6,643 shares of the company's stock valued at $383,000 after purchasing an additional 200 shares during the period. Financial Advocates Investment Management lifted its stake in shares of Sanofi by 3.4% in the 3rd quarter. Financial Advocates Investment Management now owns 6,327 shares of the company's stock valued at $365,000 after purchasing an additional 206 shares during the last quarter. Angeles Investment Advisors LLC lifted its stake in shares of Sanofi by 1.9% in the 3rd quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company's stock valued at $653,000 after purchasing an additional 210 shares during the last quarter. Finally, Keudell Morrison Wealth Management boosted its holdings in shares of Sanofi by 1.7% in the 4th quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company's stock worth $624,000 after purchasing an additional 217 shares during the period. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

SNY has been the subject of a number of analyst reports. StockNews.com downgraded Sanofi from a "buy" rating to a "hold" rating in a research report on Thursday, December 12th. Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Sanofi presently has an average rating of "Buy" and an average target price of $60.00.

Sanofi Trading Up 0.1 %

Sanofi stock traded up $0.06 during mid-day trading on Wednesday, hitting $54.95. The company's stock had a trading volume of 1,823,142 shares, compared to its average volume of 2,414,638. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The company has a 50 day moving average of $51.22 and a 200-day moving average of $52.56. Sanofi has a one year low of $45.22 and a one year high of $58.97. The stock has a market cap of $139.45 billion, a PE ratio of 22.07, a P/E/G ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts' consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, research analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.